Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The drug fitusiran, which will go by the brand name Qfitlia, is the first new treatment for both types of hemophilia — A and B. It can also be given to both patients who have antibodies that ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages ...

Fitusiran is being developed for haemophilia A and B in partnership with RNA interference (RNAi) specialist Alnylam – but has already been affected by safety issues.

approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood ...

Into this crowded treatment landscape comes another new medicine as the FDA has signed off on Sanofi’s Qfitlia (fitusiran), which sets itself apart as the only treatment for all types of hemophilia.

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on the safety and efficacy of fitusiran (Qfitlia; Sanofi). Fitusiran (Qfitlia ...

The US Food and Drug Administration (FDA) has approved fitusiran (Qfitlia, Sanofi) for bleeding prophylaxis in patients aged 12 years or older with hemophilia A and B with or without factor VIII ...

Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia ...